SOHO State of the Art Updates and Next Questions: Myelofibrosis

Publication date: Available online 22 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kristen Pettit, Srdan Verstovsek, Moshe TalpazAbstractThe discovery of a mutation in the Janus Kinase 2 (JAK2) gene in 2005 spurred significant progress in the field of myeloproliferative neoplasm (MPNs). A comprehensive description of genomic factors at play in the malignant clone in MPNs, particularly myelofibrosis (MF), have recently led to more precise, personalized prognostic tools. Despite this, understanding of the disease pathogenesis remains relatively limited. We continue to lack a detailed description of the interaction between the hematopoietic stem cell clone, abnormal bone marrow niche cells, and circulating signaling molecules and understanding of how they cooperate to promote cell proliferation, fibrogenesis, and extramedullary hematopoiesis. Despite our knowledge gaps, recent research in MF has led to promising clinical translation. In this article, we summarize recent insights into MF pathophysiology, progress in the development of novel therapeutics, and opportunities for further advancement of the field.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research